Skip to content
Screener

InfuSystem Holdings INFU Q2 2026 earnings

Reported August 4, 2026 · Before market open

Revenue$36.9MBeat by $580.0K
EPS$0.15Beat by $0.05
Revenue estimate$36.4M
EPS estimate$0.11
“We delivered another strong quarter, achieving record revenue of $36.9 million and growing Adjusted EBITDA by 7.6%. Our Oncology business continued its steady momentum, surpassing $20 million in quarterly revenue for the first time, while Wound Care delivered exceptional growth driven by strong adoption of our new lymphedema compression therapy offerings. As our business continues to diversify, we remain focused on pursuing profitable growth while driving ever greater efficiencies.”
Carrie Lachance

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$37.3M
EPS estimate$0.13

Valuation & ratios

Valuation

as of 09/16/26
See full
Market cap$244.18M+18.4%
Enterprise value$266.18M+12.1%
P/E30.9×-9.8×
P/S1.7×+0.2×

FAQ

When did InfuSystem Holdings report Q2 2026 earnings?
InfuSystem Holdings (INFU) reported Q2 2026 earnings on August 4, 2026 before market open.
What were InfuSystem Holdings's Q2 2026 revenue and EPS?
InfuSystem Holdings reported revenue of $36.9M and eps of $0.15 for Q2 2026.
Did InfuSystem Holdings beat estimates in Q2 2026?
Revenue beat the consensus estimate of $36.4M by $580.0K. EPS beat the consensus estimate of $0.10 by $0.04.
How did InfuSystem Holdings's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 2.6% from $36.0M a year earlier and eps grew 25.0% from $0.12.
Where can I find InfuSystem Holdings's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-052112) and the 10-Q periodic report (0001628280-26-052462) directly on SEC EDGAR. The filing index links above go to sec.gov.